FDA approves AbbVie-Genmab’s Epkinly to treat DLBCL
Pharmaceutical Technology
MAY 22, 2023
The US Food and Drug Administration (FDA) has granted approval to AbbVie and Genmab ‘s Epkinly (epcoritamab-bysp) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients. The FDA approval of Epkinly represents a new treatment mechanism of action for third-line DLBCL patients. “As
52 
Let's personalize your content